Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17332124 | 0.88 | SRD5A1 (0.41) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332156 | 0.88 | BAZ2B (0.38) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332125 | 0.85 | PRF1 (0.37) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17343506 | 0.85 | MAOA (0.40) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332100 | 0.84 | MAOB (0.34) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL18924819 | 0.83 | MAOA (0.40) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332062 | 0.82 | MAOA (0.34) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332139 | 0.82 | MAOA (0.40) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332108 | 0.82 | MAOA (0.40) | ROCK2MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332142 | 0.82 | MAOB (0.34) | MAOAMAOBPRKCIBAZ2BHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10584109-B2 | Processes for preparing antiviral compounds | Gillead Pharmasset LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| US-9890134-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3154984-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| WO-2015191437-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584109-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | ROCK2 3608/4885MAOA 1588/4885MAOB 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.